Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R21AI063384, U54AI057158, R01AI075092, R01AI068038, R01GM100477, R21AI098802, R33AI098802, R21AI098802, R01AI118224, R01AI136795, P30CA008748, T32 GM073546, F31 AI129244, T32 GM115327)
National Science Foundation (GFRP 2015190598)
Article History
Received: 14 January 2019
Revised: 19 February 2019
Accepted: 26 February 2019
First Online: 15 April 2019
Compliance with ethical standards
:
: D.S.T. is a coinventor of U.S. Patents 8,461,128 and 8,946,188; International Patent Applications PCT/US2016/055136 and PCT/US2016/055200; and U.S. Provisional Patent Applications 62/527,925, 62/527,932, 62/527,936, 62/527,943, 62/784,323, and 62/802,650 concerning sulfonyladenosine analogues. L.C.S. is a coinventor of U.S. Provisional Patent Application 62/784,323. M.C.L. declares no conflicts of interest.